Lumacaftor clinical trials
Also written VX-809.
Counted the way a researcher would: Lumacaftor with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses lumacaftor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lumacaftor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Jul 2015 · ORKAMBI · NDA 206038 (FDA, Drugs@FDA; in a combination)
- European Union
- 19 Nov 2015 · Orkambi · EMEA/H/C/003954 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2013 (8)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2013 | 8 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 1
Vertex Pharmaceuticals Incorporated (21) · Istituto Auxologico Italiano (1) · Qanatpharma Canada LTD (1) · Qanatpharma AG (1)
Often tested with
Tested in the same studies.
Ivacaftor (16) · Lumacaftor, ivacaftor drug combination (1) · Ciprofloxacin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test lumacaftor.
- May 2027Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure PatientsPhase 2 · Qanatpharma AG
Studies
Open first, then newest update. How each study uses lumacaftor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure PatientsRecruitingPhase 2Qanatpharma AGNCT07695090Written as Lumacaftor 200 MG
- Mutation-specific Therapy for the Long QT SyndromeCompletedPhase 2Istituto Auxologico ItalianoNCT04581408Written as Lumacaftor / Ivacaftor, Orkambi® Oral Tablet
- Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04235140Written as LUM/IVA
- Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated TabletsCompletedPhase 1Qanatpharma Canada LTDNCT05968612Written as Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet
- Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508delCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03601637Written as LUM
- A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03625466Written as LUM/IVA
- Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With IvacaftorCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02544451Written as LUM/IVA
- A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03125395Written as LUM/IVA
- A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCompletedPhase 4Vertex Pharmaceuticals IncorporatedNCT02875366Written as LUM/IVA
- Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR MutationCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03061331Written as LUM/IVA
- Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung DiseaseCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02390219Written as Lumacaftor
- A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02514473Written as VX-809
- Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT01897233Written as Lumacaftor
- A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT01931839Written as Lumacaftor Plus Ivacaftor Combination
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT01807949Written as Lumacaftor Plus Ivacaftor Combination
- Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutationCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01225211Written as Lumacaftor
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT01807923Written as Lumacaftor Plus Ivacaftor Combination
- Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene MutationCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT00865904Written as VX-809
- Phase 1, QT/QTC Interval Study in Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01910415Written as Lumacaftor
- A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With IvacaftorCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01899105Written as lumacaftor
See all 24 studies that test lumacaftor →
Given beside what is tested · 1 — lumacaftor is usual care or a partner of the new treatment
Codes
What other systems call lumacaftor · ClinicalTrials.gg INT005963
- MeSH (NLM) C569105lumacaftorOne source NLM
- UNII (FDA) EGP8L81APKLUMACAFTORConfirmed FDA, NLM, Wikidata
- RxNorm 1655922Confirmed FDA, Wikidata
- Wikidata Q6703005lumacaftorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170136LumacaftorOne source FDA
- DrugBank DB09280One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569105 | lumacaftor | One source NLM |
| UNII (FDA) | EGP8L81APK | LUMACAFTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1655922 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6703005 | lumacaftor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170136 | Lumacaftor | One source FDA |
| DrugBank | DB09280 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.